0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Treatment of Stage I Breast Cancer: The NSABP Experience

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The results of two clinical trials carried out by the National Surgical Adjuvant Breast and Bowel Project are presented. A total of 559 histologically node-negative patients were randomised and assigned treatment in the two protocols. In the oestrogen receptor-negative patients with breast cancer, treatment with methotrexate and 5-fluorouracil produced a 31% reduction in treatment failure at 4 years when compared to no systemic treatment. In the oestrogen receptor-positive patients, treatment with tamoxifen produced a 26% reduction in treatment failure at 4 years in comparison to placebo treatment. In both protocols, this benefit was observed both in patients aged under and over 50 years.

          Related collections

          Author and article information

          Journal
          HRE
          10.1159/issn.0018-5051
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5105-2
          978-3-318-01977-3
          0018-5051
          2571-6603
          1989
          1989
          02 December 2008
          : 32
          : Suppl 1
          : 175-180
          Affiliations
          National Surgical Adjuvant Project for Breast and Bowel Cancers (NSABP), University of Pittsburgh, Pa. USA
          Article
          181340 Horm Res 1989;32:175–180
          10.1159/000181340
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Breast Cancer

          Comments

          Comment on this article